Cardiovascular risk in patients with treated familial hypercholesterolaemia and patients with severe hypertriglyceridaemia.
作者信息
Mikhailidis D P, Barradas M A, Dandona P
出版信息
J R Soc Med. 1987 Jan;80(1):61. doi: 10.1177/014107688708000127.
Abstract
摘要
相似文献
1
Cardiovascular risk in patients with treated familial hypercholesterolaemia and patients with severe hypertriglyceridaemia.接受治疗的家族性高胆固醇血症患者和严重高甘油三酯血症患者的心血管风险。
J R Soc Med. 1987 Jan;80(1):61. doi: 10.1177/014107688708000127.
2
[The treatment of familial hypercholesterolemia and of the dyslipidemias responsible for cardiovascular disease].[家族性高胆固醇血症及导致心血管疾病的血脂异常的治疗]
G Ital Cardiol. 1999 Feb;29(2):171-3.
3
Cardiovascular risk in patients with treated familial hypercholesterolaemia and patients with severe hypertriglyceridaemia.接受治疗的家族性高胆固醇血症患者和严重高甘油三酯血症患者的心血管风险。
J R Soc Med. 1986 Jul;79(7):391-4. doi: 10.1177/014107688607900705.
4
Cellular senescence, telomeres, and cardiovascular risk in familial hypercholesterolaemia.家族性高胆固醇血症中的细胞衰老、端粒与心血管风险
Eur J Prev Cardiol. 2022 May 5;29(5):718-720. doi: 10.1093/eurjpc/zwaa145.
5
Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk.家族性高胆固醇血症与2019冠状病毒病：引发持续升高的心血管风险
J Intern Med. 2020 Jun;287(6):746-747. doi: 10.1111/joim.13070. Epub 2020 Apr 22.
6
Familial combined hyperlipidaemia/polygenic mixed hyperlipidaemia.家族性复合型高脂血症/多基因混合性高脂血症。
Clin Investig Arterioscler. 2021 May;33 Suppl 2:43-49. doi: 10.1016/j.arteri.2020.12.013.
7
Cardiovascular disease in patients with genotyped familial hypercholesterolemia in Norway during 1994-2009, a registry study.1994 - 2009年挪威基因分型家族性高胆固醇血症患者的心血管疾病，一项登记研究
Eur J Prev Cardiol. 2016 Dec;23(18):1962-1969. doi: 10.1177/2047487316666371. Epub 2016 Sep 27.
8
Practical definitions of severe versus familial hypercholesterolaemia and hypertriglyceridaemia for adult clinical practice.实用定义严重与家族性高胆固醇血症和高三酰甘油血症的成年临床实践。
Lancet Diabetes Endocrinol. 2019 Nov;7(11):880-886. doi: 10.1016/S2213-8587(19)30156-1. Epub 2019 Aug 21.
9
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.定义严重家族性高胆固醇血症及其对临床管理的影响：国际动脉粥样硬化学会严重家族性高胆固醇血症专家组的共识声明。
Lancet Diabetes Endocrinol. 2016 Oct;4(10):850-61. doi: 10.1016/S2213-8587(16)30041-9. Epub 2016 May 27.
10
Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.家族性高胆固醇血症患者的心血管疾病预防：PCSK9 抑制剂的作用。
Eur J Prev Cardiol. 2017 Sep;24(13):1383-1401. doi: 10.1177/2047487317717346. Epub 2017 Jun 23.
引用本文的文献
1
Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years.
Lipids. 1992 Jul;27(7):533-8. doi: 10.1007/BF02536136.
本文引用的文献
1
Hypertriglyceridaemia and hypercoagulability.
Lancet. 1983 Apr 9;1(8328):786-90. doi: 10.1016/s0140-6736(83)91849-4.
2
Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release: pathological implications in vascular disease.纤维蛋白原介导的血小板聚集激活及血栓素A2释放：对血管疾病的病理意义
J Clin Pathol. 1985 Oct;38(10):1166-71. doi: 10.1136/jcp.38.10.1166.
3
The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia.非诺贝特治疗高甘油三酯血症期间的纤溶系统与凝血
Atherosclerosis. 1986 Jul;61(1):81-5. doi: 10.1016/0021-9150(86)90116-4.
4
5
Effects of prostaglandin E2, analogs, fatty acids, and indomethacin on fibrinogen level.前列腺素E2、类似物、脂肪酸和吲哚美辛对纤维蛋白原水平的影响。
Am J Physiol. 1978 Aug;235(2):H223-30. doi: 10.1152/ajpheart.1978.235.2.H223.
Zotero 插件